Kura Oncology, Inc.
$8.65
-3.5%Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -2.7).
Valuation inputs: P/E -2.7, earnings yield N/A, momentum -3.5%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -1.6%, ROIC -48.8%).
Profitability stack: net margin -4.1%, ROE -1.6%, ROIC -48.8%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceDownside profile is elevated and scenario stress-testing is essential.
Risk factors: liabilities/assets +76.4%, momentum -3.5%, net margin -4.1%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Kura Oncology, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Kura Oncology, Inc. Fair Value Envelope
Kura Oncology, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Kura Oncology, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Cash Flow Quality Insight
Deteriorating cash generation: Both declining FCF and weak conversion rate signal fundamental challenges. Investigate margin pressure, rising costs, or working capital issues.
Kura Oncology, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Mixed signals: Strong short-term liquidity provides comfort, but high overall leverage requires careful monitoring of debt servicing capabilities and refinancing risk.
Kura Oncology, Inc. Street Expectations Map
Wall Street analysts project that KURA stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 21.20, with estimates ranging from a low of 15.00 to a high of 24.00.
The consensus 1-year price target stands at 21.20, with estimates ranging from a low of 15.00 to a high of 24.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
Mixed analyst views. Wide target range suggests differing opinions on key value drivers, growth prospects, or risk factors.
Analyst Conviction
Neutral sentiment. Fair value pricing with moderate agreement suggests wait-and-see approach or catalyst-driven opportunity.
Market Sentiment Insight
Monitor and evaluate: Current analyst consensus suggests limited conviction or near-term catalysts. Stay informed on company developments and reassess positioning as new information emerges.
Kura Oncology, Inc. Insider Positioning
During the last 12 months, insiders have purchased $2.02M and sold $1.73M worth of KURA shares, resulting in $290K of net buying activity.
3 Months
0
0.00
14.9K
154.76K
-155K
-$155K
3-6 Months
0
0.00
38.6K
382.66K
-383K
-$383K
6-9 Months
50.0K
410.14K
122.7K
1.20M
-787K
-$787K
9-12 Months
249.5K
1.61M
0
0.00
+1.6M
+$1.61M
Top Buyers
Wilson Troy Edward
Director, Officer: President & Ceo
$713K
Hasnain Faheem
Director
$187K
Vasconcelles Michael
Director
$187K
Parks Diane L.
Director
$187K
Collins Helen Louise
Director
$187K
Top Sellers
Powl Brian T.
Officer: Chief Commercial Officer
$333K
Wilson Troy Edward
Director, Officer: President And Ceo
$327K
Leoni Mollie
Officer: Chief Medical Officer
$283K
Burrows Francis
Officer: Chief Scientific Officer
$232K
Bair Teresa Brophy
Officer: Chief Legal Officer
$198K
Insider Activity Analysis
Net Insider Sentiment
Moderately bullish with $290K net buying. Insiders show cautious optimism through measured share purchases.
Buy/Sell Ratio
Positive buy/sell ratio. Buying exceeds or matches selling, indicating net positive insider sentiment.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider buyers and 5 sellers. Equal participation suggests mixed or neutral insider views.
Insider Activity Insight
Broad-based insider buying: When multiple insiders independently decide to purchase shares, it often reflects genuine confidence rather than coordinated optics. This pattern deserves attention, especially if buying followed a price decline.
No Dividend Yield Data
KURA has not reported any dividend yield values in the available annual periods.
kura Dividend History
Learning Layer
Related Guides
Build conviction on KURA by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.